Search results
Results From The WOW.Com Content Network
Mr. Justice Aftab Alam [1] Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the ...
Glaxo's $3 billion settlement included the largest civil False Claims Act settlement on record, [1] and Pfizer’s $2.3 billion ($3.5 billion in 2022) settlement including a record-breaking $1.3 billion criminal fine. [2] Legal claims against the pharmaceutical industry have varied widely over the past two decades, including Medicare and ...
Theranos Inc. ( / ˈθɛr.ən.oʊs /) was an American privately held corporation [5] that was touted as a breakthrough health technology company. Founded in 2003 by then 19-year-old Elizabeth Holmes, Theranos raised more than US$ 700 million from venture capitalists and private investors, resulting in a $10 billion valuation at its peak in 2013 ...
August 5, 2024 at 4:42 PM. By Blake Brittain. (Reuters) - Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her ...
The current lawsuit details many examples where Novartis allegedly reimbursed physicians by wining and dining to encourage them to prescribe more of its products.
In both cases, the patent trolls demanded tens of thousands of dollars. For many small businesses, it costs less to simply pay. If all patents issued were high-quality – novel, useful, and ...
Elizabeth Holmes. Elizabeth Anne Holmes (born February 3, 1984) is an American biotechnology entrepreneur who was convicted of fraud in connection to her blood-testing company, Theranos. [ 2] The company's valuation soared after it claimed to have revolutionized blood testing by developing methods that needed only very small volumes of blood ...
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it accidentally overpaid by nearly $210 ...